Shire to acquire Dyax for initial $5.9 billion

SHARE Shire to acquire Dyax for initial $5.9 billion

LONDON — The Dublin-based drug maker Shire says it will take over U.S. biotechnology firm Dyax in a deal worth an initial $5.9 billion.

The company said Monday that Shire will pay $37.30 in cash for each Dyax share.

Shire also is pursuing Baxalta, the company spun off by Deerfield-based Baxter International in July. Shire has been an buying spree since its deal with AbbVie fell apart last year.

Dyax shareholders will receive an additional $4 a share if certain performance targets are met, which would increase the overall value of the deal by $646 million.

Based in Burlington, Massachusetts, Dyax is specialized in the development of treatments for HAE, a rare genetic disease that can be life-threatening.

The deal is expected to bolster Shire’s role in the treatment of HAE. Dyax has a number of treatment regiments being tested.

The Latest
While the Bulls made early calls on Durant after he demanded a trade from the Nets, the likelihood of KD putting on a Bulls jersey anytime soon remains more fairytale than reality. Not only do the Bulls not fit the trade profile for the star, but there’s some history there with Billy Donovan that doesn’t help.
Hunter, now sporting a new title, handles a dizzying array of duties — from managing the salary cap to assisting new players’ families — to keep the Hawks’ front office functional.
Now that his former wife is dating an old friend, he’s making false claims that the new boyfriend was her secret lover during the marriage.
On the eve of his first game as a head coach at any level, Eberflus comes in not as a dynamic savior but an old-school, driven football coach. And maybe that’s the antidote the McCaskey family has been looking for.
We cannot continue to succeed if one of our most important transportation corridors continues to fail.